Sugi Predict

Sugi Predict / Targets / IAPP

IAPP

Islet amyloid polypeptide · P10997 · IAPP on Sugi Atlas →

9,778 patent compounds predicted against IAPP, 5,617 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL344347 SCHEMBL344347 0.69 8/20
Pyrogallol Pyrogallol (SCHEMBL1056082) 0.44 6/20
SCHEMBL1404989 SCHEMBL1404989 0.71 5/20
SCHEMBL1404990 SCHEMBL1404990 0.71 5/20
SCHEMBL1405080 SCHEMBL1405080 0.69 5/20
SCHEMBL1405081 SCHEMBL1405081 0.69 5/20
SCHEMBL1426061 SCHEMBL1426061 0.67 5/20
SCHEMBL70065 SCHEMBL70065 0.60 5/20
SCHEMBL691674 SCHEMBL691674 0.56 5/20
Acetic Acid Acetic Acid (SCHEMBL724536) 0.56 5/20
SCHEMBL1563517 SCHEMBL1563517 0.56 5/20
Pyrogallol Pyrogallol (SCHEMBL225781) 0.54 5/20
SCHEMBL1606580 SCHEMBL1606580 0.49 5/20
SCHEMBL67780 SCHEMBL67780 0.46 5/20
SCHEMBL1527632 SCHEMBL1527632 0.44 5/20
SCHEMBL1527075 SCHEMBL1527075 0.41 5/20
SCHEMBL1881133 SCHEMBL1881133 1.00 4/20
SCHEMBL1881134 SCHEMBL1881134 1.00 4/20
Didemethylcurcumin Didemethylcurcumin (SCHEMBL613666) 0.77 4/20
Didemethylcurcumin Didemethylcurcumin (SCHEMBL613667) 0.77 4/20

Clinical trials — most relevant to IAPP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes PHASE4WITHDRAWN
Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant PHASE4COMPLETED
Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia PHASE4COMPLETED
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus PHASE3COMPLETED
Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis PHASE3COMPLETED
Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus PHASE3COMPLETED
A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion PHASE3COMPLETED
Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus. PHASE3COMPLETED
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes PHASE3COMPLETED
Tailoring Obesity Treatment Trial PHASE2/PHASE3WITHDRAWN
Liraglutide in Adolescents With Type 1 Diabetes PHASE3COMPLETED
Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes PHASE2COMPLETED
Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes PHASE2COMPLETED
Umbilical Cord Blood Infusion to Treat Type 1 Diabetes PHASE1/PHASE2COMPLETED
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes PHASE2RECRUITING
Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes PHASE2COMPLETED
Closed Loop System With Pramlintide Versus Exenatide PHASE1COMPLETED
Multiple Islet Peptide Administration in Type 1 Diabetes (MultiPepT1De) PHASE1COMPLETED
Liver Glycogen and Hypoglycemia in Humans PHASE1ACTIVE_NOT_RECRUITING
Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Participants PHASE1COMPLETED
Identifying Potential Effects of Liraglutide on Degenerative Changes nanCOMPLETED
Amylin and Glucagon-Like Peptide-1 (GLP-1): Influence on Gastric Emptying, Appetite and Food Intake in Humans nanCOMPLETED
Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes nanRECRUITING
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass nanCOMPLETED
Assay for the Pancreatic Polypeptide: an Help for Clinical Practice Guidelines in Classification of the Diabetes nanCOMPLETED
GIP Receptor Antagonist Studies in Humans nanCOMPLETED
Tracking Neurodegeneration in Early Wolfram Syndrome nanCOMPLETED
Insulin-Glucose-Glucagon Network: Defining a Type 1 Diabetes Progression Index nanCOMPLETED
Investigating Brain Insulin Resistance in Alzheimer Disease with IntraNasal Insulin : a Multimodal Neuroimaging Study nanWITHDRAWN
Insulin and Insulin Pulses During Fasting nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a IAPP binder may also engage these)

ProteinNameSimilarity
P12967 — 0.999 P12967 →
P17716 — 0.996 P17716 →
P22889 — 0.995 P22889 →
P12968 — 0.995 P12968 →
P12966 — 0.994 P12966 →
Q28207 — 0.992 Q28207 →
P23442 — 0.991 P23442 →
P12969 — 0.990 P12969 →
Q07334 — 0.990 Q07334 →
B3IWF7 — 0.985 B3IWF7 →
Q75V95 — 0.983 Q75V95 →
Q75V94 — 0.983 Q75V94 →
Q9N0T2 — 0.978 Q9N0T2 →
P81564 — 0.977 P81564 →
P07660 — 0.977 P07660 →
Q9IAU2 — 0.976 Q9IAU2 →
Q99MP3 — 0.976 Q99MP3 →
P15743 — 0.976 P15743 →
Q862B1 — 0.975 Q862B1 →
P01263 — 0.975 P01263 →
P01257 — 0.975 P01257 →
B3IWF8 — 0.975 B3IWF8 →
Q75V93 — 0.975 Q75V93 →
B3IWF9 — 0.974 B3IWF9 →
Q766Y6 — 0.974 Q766Y6 →
P45656 — 0.973 P45656 →
C0HKU0 — 0.973 C0HKU0 →
Q23755 — 0.973 Q23755 →
Q9MYV1 — 0.972 Q9MYV1 →
O73811 — 0.972 O73811 →